Jounce Therapeutics, Inc.
JNCEDelisted May 4, 2023- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001640455
Jounce Therapeutics, Inc. was delisted on May 4, 2023; its insiders filed their last Form 4 on May 5, 2023; 84 institutions reported holding it in 13F filings for Q1 2023, worth $64.1M in total; no superinvestor held it.
Q4 2021 vs. Q3 2021
How the institutions holding Jounce Therapeutics, Inc. changed between Q3 2021 and Q4 2021.
All holders in Q4 2021All holders in Q3 2021
| Measure | Q3 2021 | Q4 2021 | Change |
|---|---|---|---|
| Holders | 115 | 124 | +9 |
| Shares | 36.4M | 41.1M | +4.70M (+12.9%) |
| Value | $270.6M | $342.9M | +$72.2M (+26.7%) |
New holders (23)
Institutions that held Jounce Therapeutics, Inc. at the end of Q4 2021 but not at the end of Q3 2021.
Sold out (14)
Institutions that held Jounce Therapeutics, Inc. at the end of Q3 2021 and filed for Q4 2021 without it.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| Adage Capital Partners GP, L.L.C. | 2,456,023 | $18.2M |
| Marshall Wace, LLP | 169,686 | $1.26M |
| Credit Suisse AG | 165,863 | $1.23M |
| Gsa Capital Partners LLP | 96,900 | $720.0K |
| Pathway Capital Management, LP | 84,763 | $630.0K |
| Jasper Ridge Partners, L.P. | 50,858 | $378.0K |
| SG Americas Securities, LLC | 23,393 | $174.0K |
| Hershey Trust Co | 16,952 | $126.0K |
| Lazard Asset Management LLC | 12,095 | $89.0K |
| Algert Global LLC | 10,200 | $76.0K |
| Meeder Asset Management Inc | 3,578 | $27.0K |
| Penserra Capital Management LLC | 1,170 | $8.00K |
| Harbour Investments, Inc. | 78 | $1.00K |
| O'Shaughnessy Asset Management, LLC | 1 | $0 |